Keystone Investors PTE Ltd. Buys Shares of 33,526 Icon Plc $ICLR

Keystone Investors PTE Ltd. purchased a new stake in shares of Icon Plc (NASDAQ:ICLR) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 33,526 shares of the medical research company’s stock, valued at approximately $5,867,000.

Several other institutional investors have also modified their holdings of ICLR. Artisan Partners Limited Partnership increased its holdings in shares of Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after acquiring an additional 2,893,946 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Icon by 21.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after purchasing an additional 650,379 shares during the period. Principal Financial Group Inc. increased its stake in shares of Icon by 739.2% in the third quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock valued at $573,526,000 after purchasing an additional 2,886,755 shares during the period. Invesco Ltd. raised its holdings in shares of Icon by 3.3% during the second quarter. Invesco Ltd. now owns 3,085,993 shares of the medical research company’s stock valued at $448,858,000 after buying an additional 98,032 shares during the last quarter. Finally, Ninety One UK Ltd grew its holdings in Icon by 0.4% in the 3rd quarter. Ninety One UK Ltd now owns 3,006,141 shares of the medical research company’s stock worth $526,075,000 after buying an additional 12,489 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Icon Price Performance

Shares of ICLR stock opened at $108.14 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market capitalization of $8.73 billion, a PE ratio of 14.63, a PEG ratio of 2.72 and a beta of 1.27. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The stock’s fifty day moving average is $159.45 and its 200-day moving average is $170.33.

Analyst Ratings Changes

Several research analysts have recently issued reports on ICLR shares. Rothschild & Co Redburn set a $100.00 price objective on shares of Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Mizuho set a $216.00 target price on Icon in a research report on Friday, January 9th. Barclays upped their price objective on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Truist Financial reaffirmed a “hold” rating and issued a $222.00 target price (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Finally, TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $157.47.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.